Source: Stockhouse
Aurora, York Region based Helix BioPharma Corp. (“Helix”) (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that it has established a Polish subsidiary (“Helix Polska”). Helix Polska was established to facilitate and support ongoing clinical oncology research at leading research institutions in Poland.
“Establishing Helix Polska further strengthens Canadian-Polish relationships and scientific collaboration, which commenced in 2005 when Polish investors first became shareholders of Helix”, said Robert Verhagen, Chief Executive Officer of Helix. “We recognize that our relationship with the various leading Polish institutions is important to our success, and Helix Polska will allow us to more effectively communicate and interact with these groups”.
Helix is actively developing innovative products for the treatment and prevention of cancer based on its proprietary technologies. Helix’s product development initiatives are focused primarily on its novel L-DOS47 and Topical Interferon Alpha-2b new drug candidates.
Helix is currently conducting a European Phase I/II clinical study in Poland with L-DOS47 in patients with inoperable, locally advanced, recurrent or metastatic, non-squamous stage non-small cell lung cancer (“NSCLC”). The study is being conducted at four Polish centers, with oversight from Helix’s European medical director, Prof. Kazimierz Roszkowski-Śliża, PhD and under the direction of Prof. Maciej Krzakowski, MD, PhD at The Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology as the overall coordinating investigator, together with three other principal investigators: Prof. Cezary Szczylik, MD, PhD at the Military Medical Institute, Prof. Elzbieta Wiatr, MD, PhD at the National Tuberculosis and Lung Diseases Research Institute and Dr. Aleksandra Szczensa, MD, PhD at the Mazovian Center of Pulmonary Diseases and Tuberculosis in Otwock.
Topical Interferon Alpha-2b is a developmental product candidate for the treatment of certain skin/mucosal lesions caused by human papilloma virus (“HPV”), based on the Company’s proprietary Biphasix™ technology. To date, the Company has completed three Phase II clinical studies with Topical Interferon Alpha-2b; two in patients with HPV-positive, low-grade cervical dysplasia and one in patients with HPV-positive ano-genital warts. Of these two therapeutic indications, efficacy was demonstrated only against low-grade cervical dysplasia, for which the Company obtained regulatory approvals to conduct more advanced, pivotal efficacy trials. Helix has now limited ongoing activities of its Topical Interferon Alpha-2b program to sourcing and qualifying alternative interferon alpha-2b raw material samples, and finding suitable strategic partner(s) who would be willing to license or acquire the product and support the remaining development costs through to commercial launch.
This release is being issued to correct information which appeared in a press release issued by Point of View S.p. Z.o.o on August 27, 2013.
- – - – - – - – - – - – - – - – - – - – - – - – - – - – - – - – - – - – - – - – - – - – - – - – - – - – - – - – - – - – -
The Regional Municipality of York is located in the heart of the Greater Toronto Area and is home to 1.1 million residents and 42,000 business establishments, making it one of Canada’s largest municipalities and the second largest business centre in the Province of Ontario.
Comprised of nine local municipalities, York Region is a premier business location in Canada. The Region is home to operations of 14 Fortune 100 companies, four of Canada’s top 10 corporate R&D investors, Canada’s second largest Information & Communications Technology (ICT) cluster and global industry leaders in Life Sciences, CleanTech, Financial Services and Advanced Manufacturing.
As Canada’s fastest growing large municipality, York Region has one of the most educated and diverse workforces in North America, the lowest commercial property taxes in greater Toronto and an exceptional quality of life attracting top global talent.
York Region’s local municipalities include the City of Markham, the City of Vaughan, the Town of Richmond Hill, the Town of Newmarket, the Town of Aurora, the Town of Whitchurch-Stouffville, the Town of East Gwillimbury, the Town of Georgina and the Township of King.